Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin — Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabet...

por Strain, William David, Paldánius, Päivi M
Publicado 2017

Individualizing treatment targets for elderly patients with type 2 diabetes: factors influencing clinical decision making in the 24-week, randomized INTERVAL study

por Strain, W. David, Agarwal, Abhijit S., Paldánius, Päivi M.
Publicado 2017

Relationship Between Duration of Type 2 Diabetes and Effectiveness of DPP-4 Inhibitor Versus Sulfonylurea as Add-on Therapy: A Post Hoc Analysis

por Brath, Helmut, Paldánius, Päivi M., Bader, Giovanni, Mathieu, Chantal
Publicado 2017

Serum and Urinary Osteocalcin in Healthy 7- to 19-Year-Old Finnish Children and Adolescents

por Paldánius, Päivi M., Ivaska, Kaisa K., Mäkitie, Outi, Viljakainen, Heli
Publicado 2021

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment

por Thomas, Merlin C., Paldánius, Päivi M., Ayyagari, Rajeev, Ong, Siew Hwa, Groop, Per-Henrik
Publicado 2016

Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies

por Kozlovski, Plamen, Fonseca, Marilia, Mohan, Viswanathan, Lukashevich, Valentina, Odawara, Masato, Paldánius, Päivi M., Kothny, Wolfgang
Publicado 2017

Exploring early combination strategy in Latin American patients with newly diagnosed type 2 diabetes: a sub-analysis of the VERIFY study

por Vencio, Sérgio, Manosalva, Juan P., Mathieu, Chantal, Proot, Pieter, Lozno, Hernan Yupanqui, Paldánius, Päivi M.
Publicado 2021

Understanding the barriers and improving care in type 2 diabetes: Brazilian perspective in time to do more in diabetes

por Vencio, Sérgio, Paldánius, Päivi M., Blüher, Matthias, Giannella-Neto, Daniel, Caiado-Vencio, Rafael, Strain, W. David
Publicado 2017

Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus

por Evans, Marc, Kozlovski, Plamen, Paldánius, Päivi M., Foley, James E., Bhosekar, Vaishali, Serban, Carmen, Avogaro, Angelo
Publicado 2017

Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance

por Mathieu, Chantal, Kozlovski, Plamen, Paldánius, Päivi M, Foley, James E, Modgill, Vikas, Evans, Marc, Serban, Carmen
Publicado 2017

Total and Carboxylated Osteocalcin Associate with Insulin Levels in Young Adults Born with Normal or Very Low Birth Weight

por Paldánius, Päivi M., Ivaska, Kaisa K., Hovi, Petteri, Andersson, Sture, Eriksson, Johan G., Väänänen, Kalervo, Kajantie, Eero, Mäkitie, Outi
Publicado 2013

A pre‐specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM

por Matthews, David R., Paldánius, Päivi M., Stumvoll, Michael, Han, Jackie, Bader, Giovanni, Chiang, YannTong, Proot, Pieter, Del Prato, Stefano
Publicado 2019

Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus

por Yoo, Soon-Jib, Chang, Sang-Ah, Sohn, Tae Seo, Kwon, Hyuk-Sang, Lee, Jong Min, Moon, Sungdae, Proot, Pieter, Paldánius, Päivi M, Yoon, Kun Ho
Publicado 2021